Podcasts about investigator perspectives

Featuring perspectives from Dr Matthew Gubens, including the following topics: Introduction: Risk of Autoimmune Toxicity with Checkpoint Inhibitors (0:00) Immunotherapy in the Neoadjuvant/Adjuvant Setting (7:33) Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (15:45) First-Line Immunotherapy for Metastatic NSCLC (24:04) Novel Agents and Strategies (30:39) Immunotherapy for NSCLC with a Targetable Mutation (41:34) Small Cell Lung Cancer (47:06) CME information and select publications

Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 data sets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/NontargetedLung).

Featuring perspectives from Dr Dana M Chase, including the following topics: Introduction: ASCO 2024 Review (0:00) Ovarian Cancer (14:29) HER2 as a Therapeutic Target (29:18) Endometrial Cancer (38:55) Cervical Cancer (51:11) CME information and select publications

Dr Dana M Chase from the David Geffen School of Medicine at UCLA in Los Angeles, California, discusses select 2023 data sets on the management of ovarian, endometrial and cervical cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Gyn).

Dr Dana M Chase from the David Geffen School of Medicine at UCLA in Los Angeles, California, discusses select 2023 data sets on the management of ovarian, endometrial and cervical cancers.

Featuring perspectives from Dr Nikhil I Khushalani and Dr Jason J Luke, including the following topics: Introduction (0:00) Evidence-Based Treatment of Nonmetastatic and Metastatic Melanoma — Dr Luke (2:49) Optimizing the Management of Nonmelanoma Skin Cancers — Dr Khushalani (36:54) CME information and select publications

Dr Nikhil I Khushalani from Moffitt Cancer Center in Tampa, Florida and Dr Jason J Luke from UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania discuss recently presented findings from ASCO on the management of melanoma and nonmelanoma skin cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/PostASCO2024/Skin).

Dr Nikhil I Khushalani from Moffitt Cancer Center in Tampa, Florida and Dr Jason J Luke from UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania discuss recently presented findings from ASCO on the management of melanoma and nonmelanoma skin cancers.

Featuring perspectives from Dr Rana R McKay and Prof Thomas Powles, including the following topics: Introduction (0:00) Management of Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Prof Powles (12:39) Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC — Dr McKay (49:27) CME information and select publications

Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma.

Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here. (https://www.researchtopractice.com/PostASCO2024/RCC)

Featuring perspectives from Dr Scott Kopetz and Dr John Strickler, including the following topics: Introduction (0:00) Recent Therapeutic Advances in Colorectal Cancer (CRC) — Dr Strickler (1:53) New Developments in Targeted Therapy for Metastatic CRC — Dr Kopetz (35:11) CME information and select publications

Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston, and Dr John Strickler from Duke University in Durham, North Carolina, discuss recent updates on available and novel treatment strategies for colorectal cancer.

Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston, and Dr John Strickler from Duke University in Durham, North Carolina, discuss recent updates on available and novel treatment strategies for colorectal cancer.

Featuring perspectives from Dr Joshua Brody, Dr Ian W Flinn and Dr Tycel Phillips, including the following topics: Introduction: CD3 Bispecific Antibodies in the Community Oncology Setting (0:00) Integration of Bispecific Antibody Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Phillips (18:13) Current and Future Role of Bispecific Antibodies in Follicular Lymphoma and Other B-Cell Lymphomas — Dr Flinn (41:20) Tolerability and Other Practical Considerations with the Use of Bispecific Antibody Therapy — Dr Brody(50:49) CME information and select publications

Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASCO2024/BispecificLymphoma).

Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston, and Dr John Strickler from Duke University in Durham, North Carolina, discuss recent updates on available and novel treatment strategies for colorectal cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASCO2024/CRC).

Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas.

Featuring perspectives from Dr Aaron T Gerds, including the following topics: Introduction: Myelofibrosis (MF) for Oncology “Newbies” (0:00) Biology of MF (5:20) Management of Anemia in MF (20:12) Novel Strategies for MF (29:28) Journal Club (46:12) CME information and select publications

Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis.

Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/MF).

Featuring perspectives from Dr Justin F Gainor and Dr Karen Reckamp, including the following topics: Introduction: Bringing Research into Practice (0:00) EGFR Activating Mutations (14:01) Exon 20 Insertion Mutations (38:06) MET Exon 14 Alterations (41:49) HER2 Mutations and Overexpression (50:27) CME information and select publications

Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets.

Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/TargetedLung).

Featuring perspectives from Dr Naval Daver and Dr Courtney D DiNardo, including the following topics: Introduction (0:00) Available and Emerging Nontargeted Therapies for Acute Myeloid Leukemia (AML) —Dr Daver (6:47) Current and Emerging Role of Biomarker-Directed Therapeutic Approaches for Patients with AML —Dr DiNardo (32:58) CME information and select publications

Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease.

Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/AML).

Featuring perspectives from Prof Thierry André and Dr Arvind Dasari, including the following topics: Introduction: Year in Review on the Ground (0:00) Treatment of HER2-Positive Colorectal Cancer (CRC) (7:50) Immune Checkpoint Inhibitors for Microsatellite Instability-High CRC (24:12) Other Key Issues (45:30) Questions and Cases from the Community (52:30) CME information and select publications

Professor Thierry André from the Hôpital Saint-Antoine in Paris, France, and Dr Arvind Dasari from MD Anderson Cancer Center in Houston, Texas, discuss recent developments regarding available and novel treatment strategies for colorectal cancer.

Professor Thierry André from the Hôpital Saint-Antoine in Paris, France, and Dr Arvind Dasari from MD Anderson Cancer Center in Houston, Texas, discuss recent developments regarding available and novel treatment strategies for colorectal cancer.

Featuring perspectives from Dr Shilpa Gupta and Prof Thomas Powles, including the following topics: Introduction: The Cancer-Immunity Cycle (0:00) Nonmetastatic Urothelial Bladder Cancer — Dr Gupta (7:30) Metastatic Urothelial Bladder Cancer — Prof Powles (33:06) CME information and select publications

Dr Shilpa Gupta from the Taussig Cancer Institute in Cleveland, Ohio, and Prof Thomas Powles from the Barts Cancer Institute in London, United Kingdom, discuss clinical decision-making with numerous treatment strategies for urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Bladder).

Professor Thierry André from the Hôpital Saint-Antoine in Paris, France, and Dr Arvind Dasari from MD Anderson Cancer Center in Houston, Texas, discuss recent developments regarding available and novel treatment strategies for colorectal cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/CRC).

Dr Shilpa Gupta from the Taussig Cancer Institute in Cleveland, Ohio, and Prof Thomas Powles from the Barts Cancer Institute in London, United Kingdom, discuss clinical decision-making with numerous treatment strategies for urothelial bladder cancer.

Featuring perspectives from Dr Andrew J Armstrong and Dr Maha Hussain, including the following topics:  Introduction: Carpool Karaoke — RTP Style (0:00) Hormonal Therapy (13:36) Other Treatment Approaches (36:50) CME information and select publications   

Dr Andrew J Armstrong from the Duke Cancer Institute Center in Durham, North Carolina and Dr Maha Hussain from Robert H Lurie Comprehensive Cancer Center in Chicago summarize recent data sets from 2023 on hormonal therapies and other emerging treatment approaches for patients with prostate cancer.

Featuring perspectives from Dr Andrew M Evens and Dr Sonali M Smith, including the following topics:  Introduction: CD3-Based Bispecific Antibodies and the General Medical Oncologist: Lymphomas, Multiple Myeloma … and Solid Tumors? (0:00) Follicular and Mantle Cell Lymphoma (7:17) Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma (30:10) CME information and select publications   

Dr Andrew J Armstrong from the Duke Cancer Institute Center in Durham, North Carolina and Dr Maha Hussain from Robert H Lurie Comprehensive Cancer Center in Chicago summarize recent data sets from 2023 on hormonal therapies and other emerging treatment approaches for patients with prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Prostate).

Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma.

Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Lymphoma).

Featuring perspectives from Dr Ian E Krop and Dr Priyanka Sharma, including the following topics:  Introduction: Educating Non-Breast Cancer Specialty Oncologists About HER2-Targeted Therapies – ASCO Genitourinary Cancers Symposium 2024 (0:00) HER2-Positive Breast Cancer — Dr Krop (12:30) Triple-Negative Breast Cancer — Dr Sharma (36:34) CME information and select publications   

Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/HER2PosTNBC).

Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer.

Featuring perspectives from Dr Yelena Y Janjigian and Dr Zev Wainberg, including the following topics: Introduction: First-Line Therapy for Metastatic Gastroesophageal (GE) Cancers — the Bottom Line (0:00) Updates on Immunotherapy in GE Cancers (18:51) Targeting HER2 (33:11) Targeting Claudin 18.2 — Zolbetuximab (54:42) CME information and select publications

Dr Yelena Y Janjigian from Memorial Sloan Kettering Cancer Center in New York and Dr Zev Wainberg from UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss the management of gastroesophageal cancers and review emerging data sets in the field, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Gastroesophageal).

Featuring perspectives from Dr Lindsey Roeker and Dr Jeff Sharman, including the following topics: An Audio Depiction of Mechanisms of Action of Bcl-2 Inhibitors, Anti-CD20 Antibodies and Covalent and Noncovalent Bruton Tyrosine Kinase Inhibitors; Mechanisms of Resistance (0:00) Current Management Approaches for Patients with Chronic Lymphocytic Leukemia (CLL) — Dr Sharman (12:27) Future Directions in the Care of Patients with CLL — Dr Roeker (33:54) CME information and select publications  

Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia.

Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/CLL).

Featuring perspectives from Dr Ahmed Omar Kaseb and Prof Arndt Vogel, including the following topics: Introduction: EMERALD-1 — Immune Checkpoint Inhibitor-Based Therapy for Localized HCC Eligible for Embolization (0:00) Optimal Utilization of Immune Checkpoint Inhibitors as First-Line Therapy for Advanced HCC – Dr Kaseb (12:49) Incorporation of Anti-PD-1/PD-L1 Antibody-Based Approaches for Advanced Biliary Tract Cancers (BTCs) — Prof Vogel (40:24) CME information and select publications

Dr Ahmed Omar Kaseb from the University of Texas MD Anderson Cancer Center in Houston, Texas, and Prof Arndt Vogel from Schwartz Reisman Liver Research Centre in Toronto, Ontario, discuss the optimal selection and sequencing of checkpoint inhibitor therapy for patients with hepatobiliary cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASCOGI24/Hepatobiliary1).